Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States
- PMID: 22865617
- PMCID: PMC4005415
- DOI: 10.1002/mpr.1359
Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States
Abstract
Estimates of 12-month and lifetime prevalence and of lifetime morbid risk (LMR) of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) anxiety and mood disorders are presented based on US epidemiological surveys among people aged 13+. The presentation is designed for use in the upcoming DSM-5 manual to provide more coherent estimates than would otherwise be available. Prevalence estimates are presented for the age groups proposed by DSM-5 workgroups as the most useful to consider for policy planning purposes. The LMR/12-month prevalence estimates ranked by frequency are as follows: major depressive episode: 29.9%/8.6%; specific phobia: 18.4/12.1%; social phobia: 13.0/7.4%; post-traumatic stress disorder: 10.1/3.7%; generalized anxiety disorder: 9.0/2.0%; separation anxiety disorder: 8.7/1.2%; panic disorder: 6.8%/2.4%; bipolar disorder: 4.1/1.8%; agoraphobia: 3.7/1.7%; obsessive-compulsive disorder: 2.7/1.2. Four broad patterns of results are most noteworthy: first, that the most common (lifetime prevalence/morbid risk) lifetime anxiety-mood disorders in the United States are major depression (16.6/29.9%), specific phobia (15.6/18.4%), and social phobia (10.7/13.0%) and the least common are agoraphobia (2.5/3.7%) and obsessive-compulsive disorder (2.3/2.7%); second, that the anxiety-mood disorders with the earlier median ages-of-onset are phobias and separation anxiety disorder (ages 15-17) and those with the latest are panic disorder, major depression, and generalized anxiety disorder (ages 23-30); third, that LMR is considerably higher than lifetime prevalence for most anxiety-mood disorders, although the magnitude of this difference is much higher for disorders with later than earlier ages-of-onset; and fourth, that the ratio of 12-month to lifetime prevalence, roughly characterizing persistence, varies meaningfully in ways consistent with independent evidence about differential persistence of these disorders.
Copyright © 2012 John Wiley & Sons, Ltd.
Figures



References
-
- Adams P.F., Hendershot G.E., Marano M.A. (1999) Current estimates from the National Health Interview Survey, 1996. Vital and Health Statistics, 10(200), 1–203. - PubMed
-
- Andrade L.H., Wang Y.P., Andreoni S., Silveira C.M., Alexandrino‐Silva C., Siu E.R., Nishimura R., Anthony J.C., Gattaz W.F., Kessler R.C., Viana M.C. (2012) Mental disorders in megacities: findings from the Sao Paulo megacity mental health survey, Brazil. PLoS One, 7(2), e31879 DOI: 10.1371/journal.pone.0031879 - DOI - PMC - PubMed
-
- Braaten E.B., Biederman J., DiMauro A., Mick E., Monuteaux M.C., Muehl K., Faraone S.V. (2001) Methodological complexities in the diagnosis of major depression in youth: an analysis of mother and youth self‐reports. Journal of Child and Adolescent Psychopharmacology, 11(4), 395–407. DOI: 10.1089/104454601317261573 - DOI - PubMed
-
- Carra G., Johnson S., Bebbington P., Angermeyer M.C., Heider D., Brugha T., Azorin J.M., Toumi M. (2012) The lifetime and past‐year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort (EuroSC). European Archives of Psychiatry and Clinical Neurosciences. DOI: 10.1007/s00406-012-0305-z - DOI - PubMed
-
- Christie K.A., Burke J.D., Jr , Regier D.A., Rae D.S., Boyd J.H., Locke B.Z. (1988) Epidemiologic evidence for early onset of mental disorders and higher risk of drug abuse in young adults. The American Journal of Psychiatry, 145(8), 971–975. - PubMed
Publication types
MeSH terms
Grants and funding
- R01 DA016558/DA/NIDA NIH HHS/United States
- R01 MH066627/MH/NIMH NIH HHS/United States
- U01-MH60220/MH/NIMH NIH HHS/United States
- R01-MH070884/MH/NIMH NIH HHS/United States
- R03 TW006481/TW/FIC NIH HHS/United States
- R01 MH069864/MH/NIMH NIH HHS/United States
- R01-DA016558/DA/NIDA NIH HHS/United States
- R01-MH069864/MH/NIMH NIH HHS/United States
- U01MH060220-09S1/MH/NIMH NIH HHS/United States
- R13-MH066849/MH/NIMH NIH HHS/United States
- R01-MH077883/MH/NIMH NIH HHS/United States
- R01 MH070884/MH/NIMH NIH HHS/United States
- U13 MH066849/MH/NIMH NIH HHS/United States
- R01 MH077883/MH/NIMH NIH HHS/United States
- R13 MH066849/MH/NIMH NIH HHS/United States
- K05 DA015799/DA/NIDA NIH HHS/United States
- R03-TW006481/TW/FIC NIH HHS/United States
- U01 MH060220/MH/NIMH NIH HHS/United States
- R01-MH66627/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical